91ÖÆƬ³§

Published on Market Research Reports® Inc. ()

Home > Global AI-driven Peptide Drug Discovery Platform Market Research Report 2024

Global AI-driven Peptide Drug Discovery Platform Market Research Report 2024

Publication ID: 
PB509240374
Publication Date: 
September 27, 2024
Pages: 
87
Publisher: 
MRRPB5
Countries: 
Global [1]
USD 2,900.00

Please choose the suitable license type from above. More details are given under tab "Report License Types" below.

IT Services [2]
Computing & Electronics [3]
Description: 

AI-driven Peptide Drug Discovery Platforms are tools that use artificial intelligence (AI) technology to accelerate and optimize the discovery and development process of peptide drugs. These platforms typically combine computational biology, machine learning, deep learning and other technologies to improve the efficiency of identifying, designing, optimizing and validating drug candidate molecules.
The global AI-driven Peptide Drug Discovery Platform market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for AI-driven Peptide Drug Discovery Platform is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for AI-driven Peptide Drug Discovery Platform is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for AI-driven Peptide Drug Discovery Platform in Scientific Research is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of AI-driven Peptide Drug Discovery Platform include Peptilogics, Pepticom Ltd, Menten AI, GUBRA, Fujitsu, Creative Peptides, LIGHT – Lifescience Innovation Good Healthcare Technology, UCB SA, Tidetronbio, Syneron, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for AI-driven Peptide Drug Discovery Platform, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding AI-driven Peptide Drug Discovery Platform.
The AI-driven Peptide Drug Discovery Platform market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global AI-driven Peptide Drug Discovery Platform market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the AI-driven Peptide Drug Discovery Platform companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Peptilogics
Pepticom Ltd
Menten AI
GUBRA
Fujitsu
Creative Peptides
LIGHT – Lifescience Innovation Good Healthcare Technology
UCB SA
Tidetronbio
Syneron
Generate Biomedicines
Peplib
Segment by Type
Cloud-based
Local Deployment
Segment by Application
Scientific Research
Pharmaceuticals
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of AI-driven Peptide Drug Discovery Platform company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents: 

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global AI-driven Peptide Drug Discovery Platform Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Cloud-based
1.2.3 Local Deployment
1.3 Market by Application
1.3.1 Global AI-driven Peptide Drug Discovery Platform Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Scientific Research
1.3.3 Pharmaceuticals
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global AI-driven Peptide Drug Discovery Platform Market Perspective (2019-2030)
2.2 Global AI-driven Peptide Drug Discovery Platform Growth Trends by Region
2.2.1 Global AI-driven Peptide Drug Discovery Platform Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 AI-driven Peptide Drug Discovery Platform Historic Market Size by Region (2019-2024)
2.2.3 AI-driven Peptide Drug Discovery Platform Forecasted Market Size by Region (2025-2030)
2.3 AI-driven Peptide Drug Discovery Platform Market Dynamics
2.3.1 AI-driven Peptide Drug Discovery Platform Industry Trends
2.3.2 AI-driven Peptide Drug Discovery Platform Market Drivers
2.3.3 AI-driven Peptide Drug Discovery Platform Market Challenges
2.3.4 AI-driven Peptide Drug Discovery Platform Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top AI-driven Peptide Drug Discovery Platform Players by Revenue
3.1.1 Global Top AI-driven Peptide Drug Discovery Platform Players by Revenue (2019-2024)
3.1.2 Global AI-driven Peptide Drug Discovery Platform Revenue Market Share by Players (2019-2024)
3.2 Global AI-driven Peptide Drug Discovery Platform Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by AI-driven Peptide Drug Discovery Platform Revenue
3.4 Global AI-driven Peptide Drug Discovery Platform Market Concentration Ratio
3.4.1 Global AI-driven Peptide Drug Discovery Platform Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by AI-driven Peptide Drug Discovery Platform Revenue in 2023
3.5 Global Key Players of AI-driven Peptide Drug Discovery Platform Head office and Area Served
3.6 Global Key Players of AI-driven Peptide Drug Discovery Platform, Product and Application
3.7 Global Key Players of AI-driven Peptide Drug Discovery Platform, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 AI-driven Peptide Drug Discovery Platform Breakdown Data by Type
4.1 Global AI-driven Peptide Drug Discovery Platform Historic Market Size by Type (2019-2024)
4.2 Global AI-driven Peptide Drug Discovery Platform Forecasted Market Size by Type (2025-2030)
5 AI-driven Peptide Drug Discovery Platform Breakdown Data by Application
5.1 Global AI-driven Peptide Drug Discovery Platform Historic Market Size by Application (2019-2024)
5.2 Global AI-driven Peptide Drug Discovery Platform Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America AI-driven Peptide Drug Discovery Platform Market Size (2019-2030)
6.2 North America AI-driven Peptide Drug Discovery Platform Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America AI-driven Peptide Drug Discovery Platform Market Size by Country (2019-2024)
6.4 North America AI-driven Peptide Drug Discovery Platform Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe AI-driven Peptide Drug Discovery Platform Market Size (2019-2030)
7.2 Europe AI-driven Peptide Drug Discovery Platform Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe AI-driven Peptide Drug Discovery Platform Market Size by Country (2019-2024)
7.4 Europe AI-driven Peptide Drug Discovery Platform Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific AI-driven Peptide Drug Discovery Platform Market Size (2019-2030)
8.2 Asia-Pacific AI-driven Peptide Drug Discovery Platform Market Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific AI-driven Peptide Drug Discovery Platform Market Size by Region (2019-2024)
8.4 Asia-Pacific AI-driven Peptide Drug Discovery Platform Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America AI-driven Peptide Drug Discovery Platform Market Size (2019-2030)
9.2 Latin America AI-driven Peptide Drug Discovery Platform Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America AI-driven Peptide Drug Discovery Platform Market Size by Country (2019-2024)
9.4 Latin America AI-driven Peptide Drug Discovery Platform Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa AI-driven Peptide Drug Discovery Platform Market Size (2019-2030)
10.2 Middle East & Africa AI-driven Peptide Drug Discovery Platform Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa AI-driven Peptide Drug Discovery Platform Market Size by Country (2019-2024)
10.4 Middle East & Africa AI-driven Peptide Drug Discovery Platform Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Peptilogics
11.1.1 Peptilogics Company Details
11.1.2 Peptilogics Business Overview
11.1.3 Peptilogics AI-driven Peptide Drug Discovery Platform Introduction
11.1.4 Peptilogics Revenue in AI-driven Peptide Drug Discovery Platform Business (2019-2024)
11.1.5 Peptilogics Recent Development
11.2 Pepticom Ltd
11.2.1 Pepticom Ltd Company Details
11.2.2 Pepticom Ltd Business Overview
11.2.3 Pepticom Ltd AI-driven Peptide Drug Discovery Platform Introduction
11.2.4 Pepticom Ltd Revenue in AI-driven Peptide Drug Discovery Platform Business (2019-2024)
11.2.5 Pepticom Ltd Recent Development
11.3 Menten AI
11.3.1 Menten AI Company Details
11.3.2 Menten AI Business Overview
11.3.3 Menten AI AI-driven Peptide Drug Discovery Platform Introduction
11.3.4 Menten AI Revenue in AI-driven Peptide Drug Discovery Platform Business (2019-2024)
11.3.5 Menten AI Recent Development
11.4 GUBRA
11.4.1 GUBRA Company Details
11.4.2 GUBRA Business Overview
11.4.3 GUBRA AI-driven Peptide Drug Discovery Platform Introduction
11.4.4 GUBRA Revenue in AI-driven Peptide Drug Discovery Platform Business (2019-2024)
11.4.5 GUBRA Recent Development
11.5 Fujitsu
11.5.1 Fujitsu Company Details
11.5.2 Fujitsu Business Overview
11.5.3 Fujitsu AI-driven Peptide Drug Discovery Platform Introduction
11.5.4 Fujitsu Revenue in AI-driven Peptide Drug Discovery Platform Business (2019-2024)
11.5.5 Fujitsu Recent Development
11.6 Creative Peptides
11.6.1 Creative Peptides Company Details
11.6.2 Creative Peptides Business Overview
11.6.3 Creative Peptides AI-driven Peptide Drug Discovery Platform Introduction
11.6.4 Creative Peptides Revenue in AI-driven Peptide Drug Discovery Platform Business (2019-2024)
11.6.5 Creative Peptides Recent Development
11.7 LIGHT – Lifescience Innovation Good Healthcare Technology
11.7.1 LIGHT – Lifescience Innovation Good Healthcare Technology Company Details
11.7.2 LIGHT – Lifescience Innovation Good Healthcare Technology Business Overview
11.7.3 LIGHT – Lifescience Innovation Good Healthcare Technology AI-driven Peptide Drug Discovery Platform Introduction
11.7.4 LIGHT – Lifescience Innovation Good Healthcare Technology Revenue in AI-driven Peptide Drug Discovery Platform Business (2019-2024)
11.7.5 LIGHT – Lifescience Innovation Good Healthcare Technology Recent Development
11.8 UCB SA
11.8.1 UCB SA Company Details
11.8.2 UCB SA Business Overview
11.8.3 UCB SA AI-driven Peptide Drug Discovery Platform Introduction
11.8.4 UCB SA Revenue in AI-driven Peptide Drug Discovery Platform Business (2019-2024)
11.8.5 UCB SA Recent Development
11.9 Tidetronbio
11.9.1 Tidetronbio Company Details
11.9.2 Tidetronbio Business Overview
11.9.3 Tidetronbio AI-driven Peptide Drug Discovery Platform Introduction
11.9.4 Tidetronbio Revenue in AI-driven Peptide Drug Discovery Platform Business (2019-2024)
11.9.5 Tidetronbio Recent Development
11.10 Syneron
11.10.1 Syneron Company Details
11.10.2 Syneron Business Overview
11.10.3 Syneron AI-driven Peptide Drug Discovery Platform Introduction
11.10.4 Syneron Revenue in AI-driven Peptide Drug Discovery Platform Business (2019-2024)
11.10.5 Syneron Recent Development
11.11 Generate Biomedicines
11.11.1 Generate Biomedicines Company Details
11.11.2 Generate Biomedicines Business Overview
11.11.3 Generate Biomedicines AI-driven Peptide Drug Discovery Platform Introduction
11.11.4 Generate Biomedicines Revenue in AI-driven Peptide Drug Discovery Platform Business (2019-2024)
11.11.5 Generate Biomedicines Recent Development
11.12 Peplib
11.12.1 Peplib Company Details
11.12.2 Peplib Business Overview
11.12.3 Peplib AI-driven Peptide Drug Discovery Platform Introduction
11.12.4 Peplib Revenue in AI-driven Peptide Drug Discovery Platform Business (2019-2024)
11.12.5 Peplib Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

Companies Mentioned: 

Peptilogics
Pepticom Ltd
Menten AI
GUBRA
Fujitsu
Creative Peptides
LIGHT – Lifescience Innovation Good Healthcare Technology
UCB SA
Tidetronbio
Syneron
Generate Biomedicines
Peplib

License Types: 

Single User License (PDF)

  • This license allows for use of a publication by one person.
  • This person may print out a single copy of the publication.
  • This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • This person cannot share the publication (or any information contained therein) with any other person or persons.
  • Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

Ìý

Site License (PDF)*

  • This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
  • These users may print out a single copy of the publication.
  • These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
  • Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

Ìý

Global License (PDF)*

  • This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
  • Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
  • These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Source URL:/mrrpb5/global-ai-driven-peptide-drug-discovery-platform-market-research-report-2024

Links
[1] /countries/global[2] /it-services[3] /computing-electronics